Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Jun;37(6):1285–1288. doi: 10.1128/aac.37.6.1285

Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations.

S E Hoffner 1, U Hjelm 1, G Källenius 1
PMCID: PMC187954  PMID: 8392308

Abstract

Mycobacterium malmoense is an opportunistic pathogen with increasingly recognized clinical importance. It is mainly isolated in northern Europe and Great Britain, most often from patients with pulmonary infections. Conventional therapy of M. malmoense infections with antituberculosis drugs is often of limited value, and there is thus a need for improved drug regimens. The potential efficacies of new alternative drugs, such as quinolones, macrolides, amikacin, and rifabutin, are still unknown, and so is the pathogen's in vitro susceptibility to most of these drugs. In this study, we used the BACTEC system for determining the pattern of resistance of clinical M. malmoense isolates to a number of antibacterial drugs as well as their possible synergistic interactions when each of them was combined with ethambutol. The majority of the strains were resistant or moderately resistant to the drug when it was tested alone at selected concentrations. However, pronounced in vitro synergism was demonstrated for combinations of ethambutol with ciprofloxacin, amikacin, and rifampin, rendering most isolates susceptible to the combined drugs. Thus, for in vitro susceptibility testing of M. malmoense, examination of the possible synergistic effects of combined drugs also can be recommended.

Full text

PDF
1288

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts W. M., Chandler K. W., Solomon D. A., Goldman A. L. Pulmonary disease caused by Mycobacterium malmoense. Am Rev Respir Dis. 1987 Jun;135(6):1375–1378. doi: 10.1164/arrd.1987.135.6.1375. [DOI] [PubMed] [Google Scholar]
  2. Banks J., Jenkins P. A., Smith A. P. Pulmonary infection with Mycobacterium malmoense--a review of treatment and response. Tubercle. 1985 Sep;66(3):197–203. doi: 10.1016/0041-3879(85)90037-6. [DOI] [PubMed] [Google Scholar]
  3. Barandun J., Salfinger M., Gräni R., Karrer W., Brändli O. Diagnose und Behandlung von pulmonalen Infekten mit Mycobacterium malmoense. Schweiz Med Wochenschr. 1991 Nov 30;121(48):1767–1772. [PubMed] [Google Scholar]
  4. Claydon E. J., Coker R. J., Harris J. R. Mycobacterium malmoense infection in HIV positive patients. J Infect. 1991 Sep;23(2):191–194. doi: 10.1016/0163-4453(91)92277-c. [DOI] [PubMed] [Google Scholar]
  5. Connolly M. J., Magee J. G., Hendrick D. J., Jenkins P. A. Mycobacterium malmoense in the north-east of England. Tubercle. 1985 Sep;66(3):211–217. doi: 10.1016/0041-3879(85)90039-x. [DOI] [PubMed] [Google Scholar]
  6. Denis C., Saltiel J. C., Choffel C., Baufine-Ducrocq H. Infection pulmonaire due à une mycobactérie rare Mycobacterium malmoënse. Rev Mal Respir. 1987;4(3):133–135. [PubMed] [Google Scholar]
  7. France A. J., McLeod D. T., Calder M. A., Seaton A. Mycobacterium malmoense infections in Scotland: an increasing problem. Thorax. 1987 Aug;42(8):593–595. doi: 10.1136/thx.42.8.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Heifets L. B., Iseman M. D., Lindholm-Levy P. J., Kanes W. Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods. Antimicrob Agents Chemother. 1985 Oct;28(4):570–575. doi: 10.1128/aac.28.4.570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hjelm U., Kaustová J., Kubín M., Hoffner S. E. Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid. Eur J Clin Microbiol Infect Dis. 1992 Jan;11(1):51–54. doi: 10.1007/BF01971272. [DOI] [PubMed] [Google Scholar]
  10. Hoffner S. E., Henriques B., Petrini B., Källenius G. Mycobacterium malmoense: an easily missed pathogen. J Clin Microbiol. 1991 Nov;29(11):2673–2674. doi: 10.1128/jcm.29.11.2673-2674.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hoffner S. E., Hjelm U. Increased growth of Mycobacterium malmoense in vitro in the presence of isoniazid. Eur J Clin Microbiol Infect Dis. 1991 Sep;10(9):787–788. doi: 10.1007/BF01972513. [DOI] [PubMed] [Google Scholar]
  12. Hoffner S. E., Kratz M., Olsson-Liljequist B., Svenson S. B., Källenius G. In-vitro synergistic activity between ethambutol and fluorinated quinolones against Mycobacterium avium complex. J Antimicrob Chemother. 1989 Sep;24(3):317–324. doi: 10.1093/jac/24.3.317. [DOI] [PubMed] [Google Scholar]
  13. Hoffner S. E., Källenius G., Beezer A. E., Svenson S. B. Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on Mycobacterium avium complex. Acta Leprol. 1989;7 (Suppl 1):195–199. [PubMed] [Google Scholar]
  14. Hoffner S. E., Svenson S. B., Källenius G. Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium. Eur J Clin Microbiol. 1987 Oct;6(5):530–535. doi: 10.1007/BF02014241. [DOI] [PubMed] [Google Scholar]
  15. Jenkins P. A., Tsukamura M. Infections with Mycobacterium malmoense in England and Wales. Tubercle. 1979 Jun;60(2):71–76. doi: 10.1016/0041-3879(79)90038-2. [DOI] [PubMed] [Google Scholar]
  16. Katila M. L., Brander E., Jantzen E., Huttunen R., Linkosalo L. Chemotypes of Mycobacterium malmoense based on glycolipid profiles. J Clin Microbiol. 1991 Feb;29(2):355–358. doi: 10.1128/jcm.29.2.355-358.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Källenius G., Svenson S. B., Hoffner S. E. Ethambutol: a key for Mycobacterium avium complex chemotherapy? Am Rev Respir Dis. 1989 Jul;140(1):264–264. doi: 10.1164/ajrccm/140.1.264. [DOI] [PubMed] [Google Scholar]
  18. Leuenberger P., Aubert J. D., Beer V. Mycobacterium malmoense--report of a case in Switzerland. Respiration. 1987;51(4):285–291. doi: 10.1159/000195215. [DOI] [PubMed] [Google Scholar]
  19. Middlebrook G., Reggiardo Z., Tigertt W. D. Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media. Am Rev Respir Dis. 1977 Jun;115(6):1066–1069. doi: 10.1164/arrd.1977.115.6.1066. [DOI] [PubMed] [Google Scholar]
  20. Portaels F., Denef M., Larsson L. Pulmonary disease caused by Mycobacterium malmoense. Comments on the possible origin of infection and methods for laboratory diagnosis. Tubercle. 1991 Sep;72(3):218–222. doi: 10.1016/0041-3879(91)90012-h. [DOI] [PubMed] [Google Scholar]
  21. Schröder K. H., Müller U. Mycobacterium malmoense in Deutschland. Zentralbl Bakteriol Mikrobiol Hyg A. 1982 Nov;253(2):279–283. [PubMed] [Google Scholar]
  22. Warren N. G., Body B. A., Silcox V. A., Matthews J. H. Pulmonary disease due to Mycobacterium malmoense. J Clin Microbiol. 1984 Aug;20(2):245–247. doi: 10.1128/jcm.20.2.245-247.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Zimmer B. L., DeYoung D. R., Roberts G. D. In vitro synergistic activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against Mycobacterium avium-intracellulare complex. Antimicrob Agents Chemother. 1982 Jul;22(1):148–150. doi: 10.1128/aac.22.1.148. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES